Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Shares Outstanding (Weighted Average): 2014-2024

Historic Shares Outstanding (Weighted Average) for Rocket Pharmaceuticals (RCKT) over the last 11 years, with Dec 2024 value amounting to $91.2 million.

  • Rocket Pharmaceuticals' Shares Outstanding (Weighted Average) rose 18.61% to $107.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.9 million, marking a year-over-year increase of 18.61%. This contributed to the annual value of $91.2 million for FY2024, which is 1.11% up from last year.
  • As of FY2024, Rocket Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $91.2 million, which was up 1.11% from $90.2 million recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' Shares Outstanding (Weighted Average) ranged from a high of $91.2 million in FY2024 and a low of $55.2 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $90.2 million (2023), whereas its average is $85.7 million.
  • Data for Rocket Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY grew of 19.12% (in 2023) over the last 5 years.
  • Rocket Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $55.2 million in 2020, then grew by 16.67% to $64.4 million in 2021, then grew by 17.44% to $75.7 million in 2022, then rose by 19.12% to $90.2 million in 2023, then climbed by 1.11% to $91.2 million in 2024.